Thalidomide-induced perioral neuropathy.
Thalidomide was administered as a therapeutic agent for chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation in a patient with breast cancer. Although side effects of thalidomide have been described earlier, this is the first instance of perioral neuropathy associated with thalidomide treatment. Awareness of this specific side effect may contribute to early diagnosis and appropriate treatment.
Elad
S
S
Department of Oral Medicine, Hadassah-Hebrew University-School of Dental Medicine, Jerusalem, Israel.
Galili
D
D
Garfunkel
A A
AA
Or
R
R
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000556:secondary; D001943:Breast Neoplasms / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D002908:Chronic Disease; D005260:Female; D006086:Graft vs Host Disease / Q000188:drug therapy; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects; D006801:Humans; D006987:Hypesthesia / Q000139:chemically induced; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D015412:Mastectomy, Segmental; D008875:Middle Aged; D009055:Mouth / Q000294:innervation*; D009364:Neoplasm Recurrence, Local / Q000473:pathology; D010292:Paresthesia / Q000139:chemically induced; D010523:Peripheral Nervous System Diseases / Q000139:chemically induced*; D012678:Sensation Disorders / Q000139:chemically induced*; D013792:Thalidomide / Q000009:adverse effects*; D014184:Transplantation, Homologous
D007166:Immunosuppressive Agents; D013792:Thalidomide